Document is current
Any future updates will be listed below
-
Authors
Proaño-Pérez, Elizabeth
Serrano-Candelas, Eva
Guerrero, Mario
Gómez-Peregrina, David
Llorens, Carlos
Soriano, Beatriz
Gámez-Valero, Ana
Herrero-Lorenzo, Marina
Martí, Eulalia
Serrano, César
Martin, Margarita https://orcid.org/0000-0002-9245-4899
-
Funding
Funding for this research was provided by:
Ministerio de Ciencia e Innovación (PID2021-122898OB-100)
Ministerio de Ciencia e Innovación (RTI-2018-096915-B100)
Instituto de Salud Carlos III (PI22_00720)
Fundación Científica Asociación Española Contra el Cáncer (AECC CLSEN20004SERR)
- License Information
-
More Information
Article History
Received: 10 October 2024
Revised: 22 September 2025
Accepted: 26 September 2025
First Online: 31 October 2025
Declarations
:
: Not applicable.
: Not applicable.
: CS has received research funding (institution) from Karyopharm, Pfizer Inc., Deciphera Pharmaceuticals, and Bayer AG; consulting fees (advisory role) from CogentBio, Immunicum AB, Deciphera Pharmaceuticals, and Blueprint Medicines; payment for lectures from PharmaMar, Bayer AG, and Blueprint Medicines; and travel grants from PharmaMar, Pfizer, Bayer AG, Novartis, and Lilly.The remaining authors have declared that no conflict of interest exists.
